The European Commission (EC) has issued marketing authorisation for Lenvima® (lenvatinib) in the treatment of people with radioactive iodine refractory differentiated thyroid cancer.
Astrazeneca presents positive data on AZD9291 in first-line EGFR mutated lung cancer
6/01/2015
AstraZeneca has announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung...
Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial
6/01/2015
Boehringer Ingelheim has announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib*...
Human papillomavirus vaccination: what are college students thinking?
6/01/2015
Preliminary results from a survey of 192 Oakland University undergraduate female students in Auburn Hills, Michigan, revealed that although a vast majority of them are aware of the human...
Amgen has announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus...
8 month delay in progression of liver tumours with radioembolisation vs. standard of care
6/01/2015
The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC)...
Biomarker analysis reveals several potential treatment targets in subtype of anal cancer
6/01/2015
While squamous cell anal carcinomas are rare, representing only about 2% of digestive-system cancer diagnoses, these cancers, which are associated with the human papillomavirus (HPV), sometimes...
Biscayne Pharmaceuticals, Inc., has announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology was discussed in a poster presentation at the...
Risk of second breast cancer operation 'halved' when surgeons cut more
6/01/2015
Risk of cancer cells around the edge of a removed tumor, and the need to go back for more surgery, were both reduced in a randomized controlled trial of breast surgical techniques.
Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, have announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral...